Effect of antiplatlet treatment on arterial elasticity

Effect of antiplatlet treatment on arterial elasticity - TRIS(Trial of HMG-CoA Reductase Inhibitor for atheroSclerosis)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001086

Enrollment

Registered

2008-03-20

Start date

2007-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes with dyslipidemia

Interventions

Pravastatin 10mg daily Atrovastatin 10mg daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type2 diabetes with dyslipidemia(LDL cholesterol over 120mg/dl)

Exclusion criteria

Exclusion criteria: severe liver dysfunction severe renal dysfunction familial hypercholesterolemia severe retinopathy severe vascular disease with urgent treatment HbA1c over 9% blood pressure over 180/100 mmHg

Design outcomes

Primary

Measure	Time frame
change of carotid arterial elasticity	—

Secondary

Measure	Time frame
changes of serum markers of atheroscrerosis,pulse wave velocity and carotid intima-media thickness	—

Countries

Japan

Contacts

Public ContactYasushi Ishigaki

Tohoku University Graduate School of Medicine Division of Molecular Metabolism and Diabetes

yishigaki@mail.tains.tohoku.ac.jp022-717-7611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026